ArticleMolecular carcinogenesis2016
Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer.
Article in Molecular carcinogenesis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 30 citations in OpenAlex.
- Immunoprevention of non-viral cancers: challenges and strategies for early intervention.Cancer cell international · 2025Review
- Recent Approaches on Oncolytic Viruses, Aptamers, TTFields and Personalized Treatment used for the Management of Glioblastoma: A Comprehensive Review.Anti-cancer agents in medicinal chemistry · 2025Review
- Immunoprevention of triple-negative breast cancer with a novel multivalent vaccine.Frontiers in immunology · 2025Article
- Rational Design of an Epidermal Growth Factor Receptor Vaccine: Immunogenicity and Antitumor Research.Biomolecules · 2024Article
- Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets.Signal transduction and targeted therapy · 2024Review
- AutoPepVax, a Novel Machine-Learning-Based Program for Vaccine Design: Application to a Pan-Cancer Vaccine Targeting EGFR Missense Mutations.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Overview and countermeasures of cancer burden in China.Science China. Life sciences · 2023Review
- Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention.NPJ precision oncology · 2023Article
- Review
- Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention.Frontiers in immunology · 2023Article
- Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR-Driven Lung Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches.Frontiers in oncology · 2022Review
- Vaccines for immunoprevention of cancer.The Journal of clinical investigation · 2021Review
- An Overview of Cancer Prevention: Chemoprevention and Immunoprevention.Journal of cancer prevention · 2020Review
- Detection and Independent Validation of Model-Based Quantitative Transcriptional Regulation Relationships Altered in Lung Cancers.Frontiers in bioengineering and biotechnology · 2020Article
- Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma.BMC immunology · 2019Article
- Article
- Autochthonous murine models for the study of smoker and never-smoker associated lung cancers.Translational lung cancer research · 2018Review
- Article
- Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.Pharmacology & therapeutics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
Abstract
The ability to prevent disease is the holy grail of medicine. For decades, efforts have been made to extend the successes seen with vaccination against infectious diseases to cancer. In some instances, preventive vaccination against viruses (prototypically HPV) has successfully prevented tumorigenesis and will make a major impact on public health in the decades to come. However, the majority of cancers that arise are a result of genetic mutation within the host, or non-viral environmental exposures. We present compelling evidence that vaccination against an overexpressed self-tumor oncoprotein has the potential to prevent tumor development. Vaccination against the Epidermal Growth Factor Receptor (EGFR) using a multipeptide vaccine in a preventive setting decreased EGFR-driven lung carcinogenesis by 76.4% in a mouse model of EGFR-driven lung cancer. We also demonstrate that anti-EGFR vaccination primes the development of a robust immune response in vivo. This study provides proof of concept for the first time that targeting tumor drivers in a preventive setting in lung cancer using peptide vaccination can inhibit tumorigenesis and may provide useful clinical insights into the development of strategies to vaccinate against EGFR in populations where EGFR-mutant disease is highly prevalent. © 2015 Wiley Periodicals, Inc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.